These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 37167174)

  • 1. [Pulmonary fibrosis in patients with COVID-19: A review].
    Chuchalin AG
    Ter Arkh; 2022 Dec; 94(11):1333-1339. PubMed ID: 37167174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulmonary fibrosis from molecular mechanisms to therapeutic interventions: lessons from post-COVID-19 patients.
    Giacomelli C; Piccarducci R; Marchetti L; Romei C; Martini C
    Biochem Pharmacol; 2021 Nov; 193():114812. PubMed ID: 34687672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics and outcomes of post-COVID-19 pulmonary fibrosis: A case-control study.
    Farghaly S; Badedi M; Ibrahim R; Sadhan MH; Alamoudi A; Alnami A; Muhajir A
    Medicine (Baltimore); 2022 Jan; 101(3):e28639. PubMed ID: 35060549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary fibrosis in COVID-19: mechanisms, consequences and targets.
    O'Reilly S
    QJM; 2023 Oct; 116(9):750-754. PubMed ID: 37191984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae?
    Bari E; Ferrarotti I; Saracino L; Perteghella S; Torre ML; Richeldi L; Corsico AG
    Cells; 2021 May; 10(5):. PubMed ID: 34068958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post covid 19 pulmonary fibrosis. Is it real threat?
    Rai DK; Sharma P; Kumar R
    Indian J Tuberc; 2021 Jul; 68(3):330-333. PubMed ID: 34099197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pulmonary manifestations in long COVID].
    Sommer N; Schmeck B
    Inn Med (Heidelb); 2022 Aug; 63(8):819-829. PubMed ID: 35925073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lung Fibrosis Sequelae After Recovery from COVID-19 Infection.
    Susanto AD; Triyoga PA; Isbaniah F; Fairuz A; Cendikiawan H; Zaron F; Aryanti I; Irbah SN; Hidayat M
    J Infect Dev Ctries; 2021 Mar; 15(3):360-365. PubMed ID: 33839710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunofibrotic drivers of impaired lung function in postacute sequelae of SARS-CoV-2 infection.
    Chun HJ; Coutavas E; Pine AB; Lee AI; Yu VL; Shallow MK; Giovacchini CX; Mathews AM; Stephenson B; Que LG; Lee PJ; Kraft BD
    JCI Insight; 2021 Jul; 6(14):. PubMed ID: 34111030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of the combination of modern medicine and traditional Chinese medicine in pulmonary fibrosis arising as a sequelae in convalescent COVID-19 patients: a randomized multicenter trial.
    Lu ZH; Yang CL; Yang GG; Pan WX; Tian LG; Zheng JX; Lv S; Zhang SY; Zheng PY; Zhang SX
    Infect Dis Poverty; 2021 Mar; 10(1):31. PubMed ID: 33731163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overactive Epidermal Growth Factor Receptor Signaling Leads to Increased Fibrosis after Severe Acute Respiratory Syndrome Coronavirus Infection.
    Venkataraman T; Coleman CM; Frieman MB
    J Virol; 2017 Jun; 91(12):. PubMed ID: 28404843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary fibrosis in patients with COVID-19: A retrospective study.
    Li F; Deng J; Song Y; Wu C; Yu B; Wang G; Li J; Zhong Y; Liang F
    Front Cell Infect Microbiol; 2022; 12():1013526. PubMed ID: 36619759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential mechanisms for lung fibrosis associated with COVID-19 infection.
    Parimon T; Espindola M; Marchevsky A; Rampolla R; Chen P; Hogaboam CM
    QJM; 2023 Jul; 116(7):487-492. PubMed ID: 36018274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-COVID-19 Pulmonary Fibrosis: Facts-Challenges and Futures: A Narrative Review.
    Duong-Quy S; Vo-Pham-Minh T; Tran-Xuan Q; Huynh-Anh T; Vo-Van T; Vu-Tran-Thien Q; Nguyen-Nhu V
    Pulm Ther; 2023 Sep; 9(3):295-307. PubMed ID: 37209374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dyspnea in post-COVID-19 patients: A review].
    Podzolkov VI; Vetluzhskaya MV; Medvedev ID; Abramova AA; Kislenko GA
    Ter Arkh; 2024 Jul; 96(7):706-712. PubMed ID: 39106515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathophysiology of Pulmonary Fibrosis in the Context of COVID-19 and Implications for Treatment: A Narrative Review.
    Tran S; Ksajikian A; Overbey J; Li P; Li Y
    Cells; 2022 Aug; 11(16):. PubMed ID: 36010566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular and Molecular Mechanism of Pulmonary Fibrosis Post-COVID-19: Focus on Galectin-1, -3, -8, -9.
    Oatis D; Simon-Repolski E; Balta C; Mihu A; Pieretti G; Alfano R; Peluso L; Trotta MC; D'Amico M; Hermenean A
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phosphodiesterase-4 inhibitor reduces lung inflammation and fibrosis in a hamster model of SARS-CoV-2 infection.
    Kolloli A; Ramasamy S; Kumar R; Nisa A; Kaplan G; Subbian S
    Front Immunol; 2023; 14():1270414. PubMed ID: 37854602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increasing incidence of lung transplantation in patients with post-COVID-19 pulmonary fibrosis.
    Khajotia R
    Pan Afr Med J; 2021; 40():169. PubMed ID: 34970411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary fibrosis secondary to COVID-19: a narrative review.
    Tanni SE; Fabro AT; de Albuquerque A; Ferreira EVM; Verrastro CGY; Sawamura MVY; Ribeiro SM; Baldi BG
    Expert Rev Respir Med; 2021 Jun; 15(6):791-803. PubMed ID: 33902377
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.